CC
AMRX icon

Centiva Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Centiva Capital’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-57,471
Closed -$465K – 1076
2025
Q2 		$465K Buy
57,471
+14,173
+33% +$107K 0.01% 992
2025
Q1 		$363K Buy
+43,298
New +$361K 0.01% 985
2024
Q3 		– Sell
-57,139
Closed -$363K – 2104
2024
Q2 		$363K Sell
57,139
-547
-0.9% -$3.47K 0.01% 1361
2024
Q1 		$350K Buy
+57,686
New +$325K 0.01% 1168
2023
Q4 		– Sell
-31,912
Closed -$135K – 1764
2023
Q3 		$135K Buy
+31,912
New +$119K ﹤0.01% 1465
2021
Q4 		– Sell
-22,752
Closed -$121K – 1174
2021
Q3 		$121K Buy
+22,752
New +$115K 0.01% 1009

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Centiva Capital's AMRX Position: Q3 2025 in Review

Centiva Capital sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 57,471 shares — an estimated $465K sold.

Centiva Capital first reported a position in AMRX in Q3 2021 and held it in 6 quarters. The position peaked at $465K in Q2 2025. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

  • Centiva Capital reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 57,471 Amneal Pharmaceuticals shares in Q3 2025, an estimated $465K.
  • Centiva Capital first reported a position in Amneal Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Centiva Capital's Amneal Pharmaceuticals position peaked at $465K in Q2 2025.
  • 248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.